Titre : Études observationnelles comme sujet

Études observationnelles comme sujet : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Études observationnelles comme sujet : Questions médicales les plus fréquentes", "headline": "Études observationnelles comme sujet : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Études observationnelles comme sujet : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-21", "dateModified": "2025-03-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Études observationnelles comme sujet" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Études cliniques comme sujet", "url": "https://questionsmedicales.fr/mesh/D000068456", "about": { "@type": "MedicalCondition", "name": "Études cliniques comme sujet", "code": { "@type": "MedicalCode", "code": "D000068456", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N06.850.520.450.250" } } }, "about": { "@type": "MedicalCondition", "name": "Études observationnelles comme sujet", "alternateName": "Observational Studies as Topic", "code": { "@type": "MedicalCode", "code": "D064887", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ritamaria Di Lorenzo", "url": "https://questionsmedicales.fr/author/Ritamaria%20Di%20Lorenzo", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Sonia Laneri", "url": "https://questionsmedicales.fr/author/Sonia%20Laneri", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Giovanni Greco", "url": "https://questionsmedicales.fr/author/Giovanni%20Greco", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Raj Kumar Thapa", "url": "https://questionsmedicales.fr/author/Raj%20Kumar%20Thapa", "affiliation": { "@type": "Organization", "name": "Section for Pharmaceutics and Social Pharmacy, Department of Pharmacy, University of Oslo, P. O. Box 1068 Blindern, NO-0316 Oslo, Norway. Electronic address: r.k.thapa@farmasi.uio.no." } }, { "@type": "Person", "name": "Hanne Cecilie Winther-Larsen", "url": "https://questionsmedicales.fr/author/Hanne%20Cecilie%20Winther-Larsen", "affiliation": { "@type": "Organization", "name": "Centre for Integrative Microbial Evolution (CIME) and Department of Pharmacology and Pharmaceutical Biosciences, University of Oslo, Sem Sælands vei 3, NO-0371 Oslo, Norway." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.", "datePublished": "2022-08-18", "url": "https://questionsmedicales.fr/article/36059480", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.901176" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36088952", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2352-4642(22)00245-0" } }, { "@type": "ScholarlyArticle", "name": "'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.", "datePublished": "2023-10-19", "url": "https://questionsmedicales.fr/article/37873026", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/03085759231203019" } }, { "@type": "ScholarlyArticle", "name": "Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.", "datePublished": "2022-08-27", "url": "https://questionsmedicales.fr/article/36145549", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/pharmaceutics14091801" } }, { "@type": "ScholarlyArticle", "name": "Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).", "datePublished": "2024-07-14", "url": "https://questionsmedicales.fr/article/39029359", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.lungcan.2024.107894" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Environnement et santé publique", "item": "https://questionsmedicales.fr/mesh/D004778" }, { "@type": "ListItem", "position": 3, "name": "Santé publique", "item": "https://questionsmedicales.fr/mesh/D011634" }, { "@type": "ListItem", "position": 4, "name": "Méthodes épidémiologiques", "item": "https://questionsmedicales.fr/mesh/D004812" }, { "@type": "ListItem", "position": 5, "name": "Caractéristiques des études épidémiologiques", "item": "https://questionsmedicales.fr/mesh/D016020" }, { "@type": "ListItem", "position": 6, "name": "Études cliniques comme sujet", "item": "https://questionsmedicales.fr/mesh/D000068456" }, { "@type": "ListItem", "position": 7, "name": "Études observationnelles comme sujet", "item": "https://questionsmedicales.fr/mesh/D064887" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Études observationnelles comme sujet - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Études observationnelles comme sujet", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Études observationnelles comme sujet", "description": "Comment les études observationnelles aident-elles au diagnostic ?\nQuels types de diagnostics sont souvent étudiés ?\nLes études observationnelles peuvent-elles remplacer des tests diagnostiques ?\nQuel est le rôle des biais dans le diagnostic ?\nComment les études observationnelles évaluent-elles la précision des diagnostics ?", "url": "https://questionsmedicales.fr/mesh/D064887?mesh_terms=Probability&page=273#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Études observationnelles comme sujet", "description": "Quels symptômes sont souvent observés dans les études ?\nComment les symptômes sont-ils mesurés dans ces études ?\nLes études observationnelles identifient-elles des symptômes nouveaux ?\nQuel est l'impact des symptômes sur la qualité de vie ?\nLes symptômes sont-ils toujours fiables dans les études ?", "url": "https://questionsmedicales.fr/mesh/D064887?mesh_terms=Probability&page=273#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Études observationnelles comme sujet", "description": "Les études observationnelles aident-elles à identifier des stratégies de prévention ?\nQuels comportements sont souvent étudiés pour la prévention ?\nComment les résultats influencent-ils les politiques de santé ?\nLes études observationnelles mesurent-elles l'impact des programmes de prévention ?\nQuels sont les défis dans l'étude de la prévention ?", "url": "https://questionsmedicales.fr/mesh/D064887?mesh_terms=Probability&page=273#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Études observationnelles comme sujet", "description": "Comment les études observationnelles évaluent-elles les traitements ?\nLes études observationnelles comparent-elles différents traitements ?\nQuels traitements sont souvent étudiés ?\nLes effets secondaires sont-ils documentés dans ces études ?\nComment les résultats des traitements sont-ils interprétés ?", "url": "https://questionsmedicales.fr/mesh/D064887?mesh_terms=Probability&page=273#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Études observationnelles comme sujet", "description": "Les études observationnelles identifient-elles des complications ?\nComment les complications sont-elles mesurées ?\nLes complications sont-elles toujours prévisibles ?\nQuel est l'impact des complications sur le traitement ?\nLes études observationnelles aident-elles à comprendre les complications ?", "url": "https://questionsmedicales.fr/mesh/D064887?mesh_terms=Probability&page=273#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Études observationnelles comme sujet", "description": "Quels facteurs de risque sont souvent étudiés ?\nComment les études observationnelles identifient-elles les facteurs de risque ?\nLes facteurs de risque sont-ils modifiables ?\nQuel est l'impact des facteurs de risque sur la santé ?\nLes études observationnelles peuvent-elles établir des liens de causalité ?", "url": "https://questionsmedicales.fr/mesh/D064887?mesh_terms=Probability&page=273#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment les études observationnelles aident-elles au diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elles identifient des facteurs associés à des maladies, améliorant ainsi le diagnostic précoce." } }, { "@type": "Question", "name": "Quels types de diagnostics sont souvent étudiés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les maladies chroniques, les infections et les troubles mentaux sont fréquemment analysés." } }, { "@type": "Question", "name": "Les études observationnelles peuvent-elles remplacer des tests diagnostiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles complètent les tests mais ne les remplacent pas, car elles ne prouvent pas de causalité." } }, { "@type": "Question", "name": "Quel est le rôle des biais dans le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les biais peuvent fausser les résultats, rendant le diagnostic moins fiable dans certaines études." } }, { "@type": "Question", "name": "Comment les études observationnelles évaluent-elles la précision des diagnostics ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles comparent les diagnostics cliniques avec des résultats de référence pour mesurer la précision." } }, { "@type": "Question", "name": "Quels symptômes sont souvent observés dans les études ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon les maladies, incluant douleur, fatigue et troubles cognitifs." } }, { "@type": "Question", "name": "Comment les symptômes sont-ils mesurés dans ces études ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont souvent évalués par des questionnaires standardisés ou des échelles de mesure." } }, { "@type": "Question", "name": "Les études observationnelles identifient-elles des symptômes nouveaux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent révéler des symptômes non documentés ou mal compris dans certaines conditions." } }, { "@type": "Question", "name": "Quel est l'impact des symptômes sur la qualité de vie ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent significativement affecter la qualité de vie, limitant les activités quotidiennes." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours fiables dans les études ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur fiabilité peut être influencée par des biais de déclaration ou des facteurs contextuels." } }, { "@type": "Question", "name": "Les études observationnelles aident-elles à identifier des stratégies de prévention ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles identifient des facteurs de risque et des comportements protecteurs pour la santé." } }, { "@type": "Question", "name": "Quels comportements sont souvent étudiés pour la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'alimentation, l'exercice physique et le tabagisme sont fréquemment analysés." } }, { "@type": "Question", "name": "Comment les résultats influencent-ils les politiques de santé ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les résultats peuvent guider les politiques de santé publique en matière de prévention des maladies." } }, { "@type": "Question", "name": "Les études observationnelles mesurent-elles l'impact des programmes de prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles évaluent l'efficacité des programmes de prévention dans des populations spécifiques." } }, { "@type": "Question", "name": "Quels sont les défis dans l'étude de la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les défis incluent le suivi à long terme et la variabilité des comportements individuels." } }, { "@type": "Question", "name": "Comment les études observationnelles évaluent-elles les traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles analysent les résultats des traitements dans des populations réelles sans randomisation." } }, { "@type": "Question", "name": "Les études observationnelles comparent-elles différents traitements ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent comparer l'efficacité de plusieurs traitements dans des conditions réelles." } }, { "@type": "Question", "name": "Quels traitements sont souvent étudiés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements médicamenteux, les interventions chirurgicales et les thérapies comportementales." } }, { "@type": "Question", "name": "Les effets secondaires sont-ils documentés dans ces études ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les études observationnelles rapportent souvent des effets secondaires observés chez les patients." } }, { "@type": "Question", "name": "Comment les résultats des traitements sont-ils interprétés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont interprétés en tenant compte des biais potentiels et des facteurs de confusion." } }, { "@type": "Question", "name": "Les études observationnelles identifient-elles des complications ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles documentent les complications associées à des maladies ou traitements spécifiques." } }, { "@type": "Question", "name": "Comment les complications sont-elles mesurées ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont mesurées par des événements indésirables rapportés ou des critères cliniques définis." } }, { "@type": "Question", "name": "Les complications sont-elles toujours prévisibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Non, certaines complications peuvent survenir de manière inattendue, rendant leur prévision difficile." } }, { "@type": "Question", "name": "Quel est l'impact des complications sur le traitement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent nécessiter des ajustements de traitement ou des interventions supplémentaires." } }, { "@type": "Question", "name": "Les études observationnelles aident-elles à comprendre les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles fournissent des données sur la fréquence et les facteurs associés aux complications." } }, { "@type": "Question", "name": "Quels facteurs de risque sont souvent étudiés ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent l'âge, le sexe, le mode de vie et les antécédents médicaux." } }, { "@type": "Question", "name": "Comment les études observationnelles identifient-elles les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Elles analysent les données de santé et les comportements des populations sur de longues périodes." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils modifiables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certains sont modifiables, comme le tabagisme et l'alimentation, tandis que d'autres ne le sont pas." } }, { "@type": "Question", "name": "Quel est l'impact des facteurs de risque sur la santé ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Ils augmentent la probabilité de développer des maladies, influençant la santé publique." } }, { "@type": "Question", "name": "Les études observationnelles peuvent-elles établir des liens de causalité ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent suggérer des associations, mais ne peuvent pas prouver la causalité directement." } } ] } ] }

Sources (2727 au total)

Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.

To identify less invasive and easily applicable serum cytokine-derived biomarkers which contribute to the diagnostic utility and risk assessment ability of the prostate health index (PHI) based multiv... Serum 45 cytokines screening was performed in a small training cohort consisting of 10 sera by Luminex liquid array-based multiplexed immunoassays and identified TRAIL and IL-10 as new biomarkers for ... TRAIL and IL-10 were identified as potential serum biomarkers for AG PCa detection by the result of multi-cytokines screening in the univariate analysis, while multivariable logistic regression confir... We suggest a significant advantage for the PHI-based multivariate combinations of serum TRAIL and IL-10 comparing to PHI or other serum-derived biomarkers alone in the detection and risk stratificatio...

Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.

Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ... In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig... Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4... An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass... The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....

'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.

This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...

Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi... This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan.... In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ... These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...

Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.

Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo... Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander... Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ... This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba... This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....

The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries.

Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antena... WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phospha... This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmaco... ISRCTN11434567 . Registered on 7 June 2021....